Helsinn, the Swiss Group focused on building quality cancer care, and Australian biopharmaceutical company Specialised Therapeutics Australia (STA), announce that the Therapeutic Goods Administration (TGA) has approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy1.